1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Adimmune Corporation

Adimmune Corporation

TTWSE:4142
17.80
TWD
-0.10
(-0.56%)
-0.49EPS
7.42BMarket Cap
Nov 18Next Earn
Adimmune Corporation
TWSE:4142
(Taiwan Stock Exchange)

Recent

price

17.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
4.94
1.68
2.07
2.13
2.26
1.17
2.46
2.28
3.49
4.19
4.57
4.18
5.27
4.24
3.69
3.32
3.18
Revenue per Share
0.95
-2.73
-3.23
-3.09
-2.89
-3.08
-2.41
-3.07
-2.62
-0.9
3.03
0.1
0.68
-1.52
-0.58
-0.57
-0.33
Basic EPS, GAAP
-0.65
-4.05
-4.21
-2.99
-2.06
-1.55
-3.22
-0.02
-2.65
-1.01
5.14
-3.09
-1.48
-2.64
1.22
-0.57
-0.53
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.5
- -
- -
- -
- -
- -
Dividend per Share
23.54
20.66
19.27
16.54
16.9
13.95
11.67
8.52
6.57
10.04
14.71
14.32
14.53
12.99
12.41
11.73
10.97
Book Value per Share
19.73
17.13
16.36
13.89
15.02
12.24
10.16
7.71
5.9
9.64
14.38
14.04
14.31
12.82
12.3
11.67
10.93
Tangible Book Value per Share
169
173
187
194
213
247
247
247
236
310
409
430
427
422
422
422
430
Basic Weighted Avg Shares
835
290
387
414
481
291
607
563
822
1,300
1,869
1,794
2,252
1,785
1,557
1,402
1,370
Sales/Revenue/Turnover
26.46
-200.13
-172.2
-156.12
-134.78
-253.67
-97.55
-125.32
-88.19
-23
-1.38
-3.02
4.38
-18.42
-19.21
-22.94
-16.2
Operating Margin (%)
211
235
274
295
299
305
292
292
258
240
228
226
259
224
216
215
211
Depreciation Expense
161
-471
-604
-600
-614
-761
-595
-760
-618
-281
1,241
43
291
-640
-243
-240
-144
Net Income, GAAP
28.98
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6.4
- -
- -
- -
- -
Effective Tax Rate (%)
19.32
-162.32
-155.97
-145
-127.87
-261.78
-98.13
-135.08
-75.13
-21.6
66.41
2.4
12.92
-35.85
-15.59
-17.12
-10.48
Profit Margin (%)
997
968
1,113
649
1,466
1,117
1,909
1,427
528
2,130
4,521
3,499
3,991
2,912
2,449
1,725
2,486
Working Capital
1,000
1,734
1,921
1,843
1,180
1,300
2,809
2,724
2,613
2,531
1,314
1,273
2,101
1,918
1,758
1,594
2,690
LT Debt
4,062
3,578
3,738
3,237
4,467
3,685
3,095
2,349
1,856
3,826
6,629
6,433
6,545
5,778
5,562
5,052
4,705
Total Equity
2.95
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.36
-0.69
1.06
- -
- -
- -
- -
Return on Invested Capital (%)
3.24
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.27
1.1
5.52
- -
- -
- -
- -
Return on Capital (%)
4.12
-12.34
-16.51
-17.22
-16.53
-19.94
-18.86
-30.48
-32.93
-10.62
24.92
0.69
4.74
-11.03
-4.53
-4.71
-3.06
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,237
1,136
337
LT Borrowings
1,548
1,545
2,652
LT Finance Leases
46
41
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
422
422
422
Market Capitalization
7,988
7,735
7,419

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,271
2,913
3,203
Cash, Cash Equivalents & STI
2,239
1,845
1,823
Accounts Receivable, Net
145
138
135
Inventories
571
593
907
Total Current Liabilities
1,546
1,385
716
Payables & Accruals
- -
- -
- -
ST Debt
1,237
1,136
337
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.24%
-5.17%
-9.17%
Free Cash Flow
1,261.42%
-86.53%
-147.19%
Net Income, GAAP
-51.36%
19.19%
-1.18%
Sales/Revenue/Turnover
22.74%
-4.4%
-9.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44
80
888
545
1,557
2025
72
109
475
745
1,402
2026
82
67
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.44
-0.65
0.62
-0.11
-0.58
2025
-0.53
-0.52
-0.04
0.52
-0.57
2026
-0.44
-0.38
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Adimmune Corporation (4142:TT), founded in 1965 and headquartered in Taichung, Taiwan, develops, manufactures, and distributes vaccines and biological products primarily in Taiwan, the United States, China, and international markets including Southeast Asia and Brazil. The company produces AdimFlu-S quadrivalent influenza vaccine, trivalent influenza vaccines, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese encephalitis vaccines, tetanus toxoid alum precipitated for tetanus prevention, purified Tuberculin, and offers contract development and manufacturing organization (CDMO) services using egg-based and cell-culture platforms at PIC/S GMP-certified facilities with annual capacity for tens of millions of doses; its subsidiary Enimmune Corp. (6564:TT) markets EnVAX-A71 enterovirus 71 vaccine. Adimmune operates in the biotechnology sector serving government programs, pharmaceutical partners, and global health organizations. In recent developments, Adimmune received ANVISA GMP certification for its Tanzi plant in August 2025 advancing Brazilian regulatory approval for influenza vaccines, installed a third automated aseptic filling line adding 4 million doses annual capacity for customized CDMO in 2025, passed EMA and ANVISA inspections in H1 2025, signed SMTA2 with WHO in May 2024 for pandemic influenza strain access, resumed tetanus vaccine production targeting Southeast Asia and China exports, and expanded Enimmune's EV71 vaccine filings in Macau, Vietnam, and Thailand while scaling cell culture production to 1,000 liters. The company previously secured EMA GMP certifications, extended Sanofi Pasteur partnership to 2027, and achieved AdimFlu-S approvals in China and Thailand.